(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 November 2013 (21.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/173158 A1

(51) International Patent Classification:
A61K 38/18 (2006.01) *A61P 19/10* (2006.01)
A61P 19/08 (2006.01)

(21) International Application Number:
PCT/US2013/040275

(22) International Filing Date:
9 May 2013 (09.05.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/646,974 15 May 2012 (15.05.2012) US
61/786,939 15 March 2013 (15.03.2013) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **MA, Yanfei Linda**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **IRIZARRY ROVIRA, Armando Rafael**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **REYNOLDS, Vincent Louis**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agents: **CASTETTER, Andrea Michelle** et al.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/173158 A1

(54) Title: THERAPEUTIC USES OF FIBROBLAST GROWTH FACTOR 21 PROTEINS

(57) Abstract: The present invention relates to therapeutic uses of human fibroblast growth factor 21 (FGF21) proteins.